Rilzabrutinib a BTK inhibitor

Multi-Immune Modulation With Rilzabrutinib

Rilzabrutinib is an oral, covalent, reversible, highly specific BTK inhibitor

BTK inhibition with rilzabrutinib modulates multiple immune pathways without causing broad immunosuppression

Rilzabrutinib's immunomodulatory effects: Rebalancing innate and adaptive immunity

In vitro and biomarker studies, rilzabrutinib’s immunomodulatory effects were confirmed:

BTK inhibition: Rilzabrutinib acts via multi-immune modulation targeting key aspects of complex immune dysregulation in multiple diseases¹⁰

Abbreviations:

BCR, B-cell receptor; BTK, Bruton’s tyrosine kinase; Cys, cysteine; FcεR, Fc epsilon receptor; FcγR, Fc gamma receptor; IC, immune complex; IgE, immunoglobulin E; IgG, immunoglobulin G; IgM, immunoglobulin M; IL, interleukin; ITP, immune thrombocytopenia; NET, neutrophil extracellular trap; NLRP, NOD-like receptor protein with a PYRIN domain; Rilza, rilzabrutinib; ROS, reactive oxygen species; SCD, sickle cell disease; TLR, toll-like receptor; TNF-α, tumor necrosis factor alpha; wAIHA, warm autoimmune hemolytic anemia.